Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
United States
Tel: 800-GILEAD-5 or 650-574-3000
Fax: 650-522-5800
Website: http://www.gilead.com/
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
YEAR FOUNDED:
1987
LEADERSHIP:
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
CLINICAL TRIAL:
Please click here for clinical trial information.
1369 articles with Gilead Sciences, Inc.
-
It has been noted that a number of billionaires—at least six—who are fifty years or older in age, have been investing in health care and longevity-related startup companies.
-
Gilead Lawsuits: California HIV Patients File Class Action and Personal Injury Cases Over Key HIV Drug
5/9/2018
Legal actions filed by patients with HIV from Los Angeles, San Diego & Marin Counties target Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s suppression of a safer version of the drug with far less toxicity in order to maximize profits and extend the sales of the initial drug, tenofovir disoproxil fumarate (“TDF”).
-
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16
5/8/2018
Webcast Available Through Gilead Corporate Website
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
-
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
-
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...
-
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
-
The two companies will use Verity’s Immunoscape platform to profile the molecular characteristics of inflammatory diseases.
-
At the end of 2016, there were an estimated 36.7 million people living with HIV across the globe. With a large and growing patient population, the market for HIV treatments is expected to grow to $22.5 billion by 2025.
-
Bill Gates via The Bill and Melinda Gates Foundation and Google co-founder Larry Page, have pledged $12 million to research to develop a universal flu vaccine. However, they aren’t the only tech billionaires to get into funding healthcare and life science research initiatives.
-
Gilead Sciences Announces Second Quarter 2018 Dividend
5/1/2018
Gilead Sciences, Inc. announced that the company’s Board of Directors has declared a cash dividend of $0.57 per share of common stock for the second quarter of 2018.
-
Gilead Sciences Announces First Quarter 2018 Financial Results
5/1/2018
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2018.
-
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
4/30/2018
Gilead Sciences, Inc. and Verily Life Sciences LLC announced a scientific collaboration using Verily’s Immunoscape platform to identify and better understand the immunological basis of three common and serious inflammatory diseases.
-
Shares of SteadyMed Ltd. have skyrocketed more than 77 percent in premarket trading today after United Therapeutics announced it will acquire the company for a total of $216 million, including $75 million in contingent consideration.
-
European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
4/27/2018
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Biktarvy®.
-
During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.
-
It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.
-
A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.
-
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
-
Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.